<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414594</url>
  </required_header>
  <id_info>
    <org_study_id>IONIS-APO(a)-LRx</org_study_id>
    <nct_id>NCT02414594</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)</brief_title>
  <official_title>A Blinded, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 681257 Administered Subcutaneously to Healthy Volunteers With Elevated Lipoprotein(a)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akcea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of
      IONIS APO(a)-LRx (ISIS 681257) given to healthy volunteer subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of single and multiple doses of IONIS-APO(a)-LRx (incidence, severity, and dose-relationship of adverse effects and changes in the laboratory parameters)</measure>
    <time_frame>Up to 113 days</time_frame>
    <description>The safety and tolerability of IONIS-APO(a)-LRx will be assessed by determining the incidence, severity, and dose-relationship of adverse effects and changes in the laboratory parameters by dose. Safety results in subjects dosed with IONIS-APO(a)-LRx will be compared with those from subjects dosed with placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetics of single and multiple doses of IONIS-APO(a)-LRx (unconjugated and conjugated ASO)</measure>
    <time_frame>Up to 113 days</time_frame>
    <description>The plasma pharmacokinetics of IONIS-APO(a)-LRx (unconjugated and conjugated ASO) will be assessed following single and multiple-dose SC administration. The amount of ISIS-APO(a)-LRx excreted in urine at selected 24-hour intervals will also be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the plasma pharmacodynamics of IONIS-APO(a)-LRx (Changes in plasma Lp(a) levels)</measure>
    <time_frame>Up to 113 days</time_frame>
    <description>Changes in plasma Lp(a) levels compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx</measure>
    <time_frame>Up to 113 days</time_frame>
    <description>Effects of IONIS-APO(a)-LRx on changes in levels of oxidized phospholipids associated with apoB-100 compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx</measure>
    <time_frame>Up to 113 days</time_frame>
    <description>Effects of IONIS-APO(a)-LRx on changes in levels of oxidized phospholipids associated with apo(a) compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx</measure>
    <time_frame>Up to 113 days</time_frame>
    <description>Effects of IONIS-APO(a)-LRx on changes in Lp-PLA2 compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx</measure>
    <time_frame>Up to 113 days</time_frame>
    <description>Effects of IONIS-APO(a)-LRx on changes in sPLA2 compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx</measure>
    <time_frame>Up to 113 days</time_frame>
    <description>Effects of IONIS-APO(a)-LRx on changes in apo(a) isoform size compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx</measure>
    <time_frame>Up to 113 days</time_frame>
    <description>Effects of ISIS-APO(a)-LRx on changes in lipid panel compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx</measure>
    <time_frame>Up to 113 days</time_frame>
    <description>Effects of IONIS-APO(a)-LRx on changes in systemic markers of inflammation compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx</measure>
    <time_frame>Up to 113 days</time_frame>
    <description>Effects of IONIS-APO(a)-LRx on changes in plasminogen/coagulation compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Elevated Lipoprotein(a) [Lp(a)]</condition>
  <arm_group>
    <arm_group_label>IONIS-APO(a)-LRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: IONIS-APO(a)-LRx</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Normal Saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Sterile Normal Saline (0.9% NaCl)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-APO(a)-LRx</intervention_name>
    <description>Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection</description>
    <arm_group_label>IONIS-APO(a)-LRx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Normal Saline (0.9% NaCl)</intervention_name>
    <description>Calculated volume to match active comparator</description>
    <arm_group_label>Placebo (Normal Saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have given written informed consent and be able to comply with all study
             requirements

          -  Healthy males or females aged 18-65 inclusive and weighing ≥ 50 kg at the time of
             informed consent

          -  Females must be non-pregnant and non-lactating, and either surgically sterile or post-
             menopausal

          -  Males must be surgically sterile, abstinent or using an acceptable contraceptive
             method

          -  BMI &lt; 35.0 kg/m2

          -  Subjects must have Lp(a) ≥ 75 nanomoles/liter nmol/L (30 mg/dL) at Screening

        Exclusion Criteria:

          -  Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C
             or chronic hepatitis B

          -  Treatment with another Study Drug, biological agent, or device within one-month of
             screening

          -  Regular use of alcohol within 6 months of Screening

          -  Use of concomitant drugs unless authorized by the Sponsor Medical Monitor

          -  Smoking &gt; 10 cigarettes a day

          -  Considered unsuitable for inclusion by the Principal Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9L 3A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2015</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

